Oreana is a new genetic test that screens for genetic conditions which affect normal development in newborns, infants or young children. Oreana is a beneficial test for:

  • Asymptomatic infants, for early identification of conditions which may not cause any symptoms initially and babies may not show any signs of illness. However, once symptoms begin, their damage may be irreparable and the health of the infant can deteriorate quickly, so early detection is beneficial.
  • Symptomatic infants which have signs or symptoms of disease that can be diffcult to be clearly identified due to complexity or variability of symptoms. In these cases, Oreana could correctly identify the genetic change (mutation) responsible for the disease, and can lead to the affected child receiving the optimal treatment.

Most of the disorders included in Oreana are either treatable or have a simple management plan such as following dietary restrictions and taking prophylactic measures. When initiated early, symptoms can be prevented or their severity may be reduced, improving the prognosis and life expectancy of affected infants.


With Oreana, early detection of life-altering disorders can benefit the infant’s health and quality of life. The initial symptoms for many of these disorders include vomiting, lack of energy, breathing problems, feeding diffculties, and episodes of metabolic crises that require urgent care. Although treatment can begin when infants first start showing symptoms, which may be a few weeks or months after birth, their growth and development will already be impacted. Early detection and starting treatment as soon as possible is the most favourable way to prevent symptoms or minimise the impact of the condition.

Early detection can:

  • Prevent or minimize symptoms
  • Reduce the impact of the condition
  • Reduce the time spent for diagnosis, and prevent a late diagnosis
  • Permit early clinical interventions, treatment and management which will be more beneficial for the infant
  • Enable potential participation of the infant in experimental therapies or clinical trials


Results are reported quickly, so if necessary, your baby can start beneficial treatment as soon as possible

Tests for disease-causing genetic changes (mutations), that cause serious health problems

Superior technology that yields accurate results

Non-invasive and painless for the infant

Complements newborn screening programs that test a smaller number of disorders


Oreana neonatal screening can detect treatable or manageable conditions before appearance of symptoms. With early treatment and management, symptoms can be averted, and health problems can be minimized or prevented. Oreana can also be used for newborns, infants and children who show symptoms of a genetic disease which could be diffcult to identify. In these cases, Oreana can lead to the appropriate therapy that will benefit the affected child.

*Data collected from Centers for Disease Control and Prevention (2012); CDC Grand Rounds: Newborn screening and improved outcomes, and is based on screening of 29 diseases included in core conditions of the Recommended Uniform Screening Panel.


National newborn screening programs offer great advantages for infants, their families and national health systems. However, since they are subjected to each country’s regulations, the structure of the healthcare system and available funds, there are vast differences in the number of conditions each country tests for and in the technology they use to do so. As a result, countries throughout the world perform newborn ranging from only 2 disorders to over 35.

Oreana neonatal screening tests for 106 genetic disorders that are either treatable or can benefit from early detection. Among others, Oreana tests for metabolic, endocrine, haemoglobin and hearing loss disorders, whose early detection and management can lead to therapeutic treatments that could reduce the severity of symptoms and improve the prognosis and life quality of the affected infant.


Testing is quick and safe for your baby. A healthcare practitioner will use a specialized, soft swab to collect sample from the inside of the cheek of the infant, by moving it around in circular movements. The procedure is painless and is completed in a few seconds. The results will be reported back to your healthcare practitioner within 2-3 weeks of sample receipt.


Your baby can get tested anytime after the first 24 hours of birth, up until early childhood. Ideally, the earlier the infant is tested, the sooner you will know whether they are affected, and start beneficial treatments that can prevent the onset of symptoms or minimize the impact of the disease.


Oreana tests for 106 genetic conditions that when detected early, can prevent or reduce serious consequences such as developmental delay, cognitive impairment, neurological and physical problems and premature death. The conditions tested may be inherited from carrier parents who are unaware of their carrier status to their children, or without a known or prior family history of that disorder.


Lifelong dietary management is required. Early diagnosis and interventions can help prevent symptoms and improve prognosis.


Early medical treatment and interventions can improve thyroid function, growth, development and metabolism. Lifelong treatment and follow-up by specialists is necessary.


Medical treatment, dietary management and transfusions are critical and needed lifelong.


Hearing aids, cochlear implants or other services can help with creating the best management plan. Early interventions can improve the speech, language and social skills of affected children.


Including Cystic Fibrosis, Severe Combined Immunodeficiences and Spinal Muscular Atrophy. Early detection is critical for prompt medical treatment, such as bone marrow transplantation, and better prognosis.

Oreana tests for 142 genes and 106 Autosomal Recessive, Autosomal Dominant and X-Linked disorders. The disorders tested by Oreana are included in the 'Recommended Uniform Screening Panel', a list of disorders selected based upon the recommendations of the American College of Medical Genetics (ACMG) for newborn screening. Additional, clinically significant, manageable disorders were added to the Oreana panel.







NIPD Genetics - Privacy Policy

General Statement

This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.

If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.

NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.

Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.

You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus

NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com

This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:

NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.

We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com

Type of personal information NIPD Genetics may collect through its Sites

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Sites and services to you.

Personal Data

While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:

If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.

Cookies and Usage Data

Usage Data

We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.

Examples of Cookies we use:

Session Cookies. We use Session Cookies to operate our Sites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the Sites

Keyword cookies. To understand how visitors discover the Sites.

Use of Data

www.nipd.com uses the collected data for various purposes:

Transfer of Data

Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.

NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:

Security of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

Service Providers

We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.


We may use third-party Service Providers to monitor and analyze the use of our Sites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

Access to your personal data, correction, deletion, and Opting Out

You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com

Links to Other Sites

Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes to This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact pdo@nipd.com

Ok got it!